AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29511785 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-paced strength training (NPST)
Number of subjects: 0
Study 29511785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26905901 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone plus prolonged exposure (PE)
Number of subjects: 0
Study 26905901 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no PE
Number of subjects: 0
Study 26905901 — intervention group
Group type: COMPARATOR
Intervention: PE plus placebo
Number of subjects: 0
Study 26905901 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone without PE
Number of subjects: 0
Study 26905901 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 26905901 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD severity
Number of subjects: 0
Study 26905901 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PTSD symptoms and percentage of days drinking
Number of subjects: 0
Study 23868419 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV care and treatment services
Number of subjects: 3538
Study 21948457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic matrix based modified release formulations
Number of subjects: 0
Study 21948457 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictions of in vivo drug release
Number of subjects: 0
Study 20881001 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-5T4
Number of subjects: 733
Study 20881001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 18538636 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 156
Study 18538636 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 156
Study 15918525 — intervention group
Group type: EXPERIMENTAL
Intervention: Myung In haloperidol (test drug)
Number of subjects: 24
Study 15918525 — intervention group
Group type: COMPARATOR
Intervention: Peridol (reference drug)
Number of subjects: 24
Study 12893330 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U of botulinum toxin A
Number of subjects: 30
Study 12893330 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 30
Study 10367550 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone tablet (50 mg) plus placebo skin patch
Number of subjects: 19
Study 10367550 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet plus nicotine skin patch (21 mg/24 h)
Number of subjects: 19
Study 10367550 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone tablet plus nicotine skin patch
Number of subjects: 19
Study 10367550 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet plus placebo skin patch
Number of subjects: 19
Study 8896495 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine trial participation willingness
Number of subjects: 1975
Study 8896495 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seroincidence
Number of subjects: 1975
Study 8896495 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seroincidence in subgroup willing to participate
Number of subjects: 1975
Study 8896495 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of HIV seroconversion
Number of subjects: 1975
Study 1854025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 microgram/kg of dexmedetomidine
Number of subjects: 96
Study 1854025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg of dexmedetomidine
Number of subjects: 96
Study 1854025 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms/kg of oxycodone
Number of subjects: 96
Study 1854025 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms/kg of diclofenac
Number of subjects: 96
Study 6340820 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg for three days, two weekly
Number of subjects: 135
Study 6340820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 30608390 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum TENS
Number of subjects: 46
Study 30608390 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 46
Study 29082505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 310
Study 29082505 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 310
Study 27296705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin/ezetimibe combination
Number of subjects: 246
Study 27296705 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone
Number of subjects: 246
Study 24810181 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib administered with food
Number of subjects: 34
Study 24810181 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib administered in the evening after a 2-h fast
Number of subjects: 34
Study 24810181 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 34
Study 22900497 — intervention group
Group type: EXPERIMENTAL
Intervention: U Clip anastomosis
Number of subjects: 31
Study 22900497 — intervention group
Group type: COMPARATOR
Intervention: Conventional anastomosis with 6/0 Prolene
Number of subjects: 31
Study 19910613 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol with fluticasone propionate
Number of subjects: 544
Study 19910613 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol alone
Number of subjects: 544
Study 17557214 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for management of varicella zoster virus infections
Number of subjects: 0
Study 15907955 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/kg of 100 proof (50% absolute ethanol) vodka
Number of subjects: 51
Study 15907955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12878949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning with 5 minutes of ischemia and 5 minutes of reoxygenation before 90 minutes of ischemia and 120 minutes of reoxygenation
Number of subjects: 128
Study 12878949 — intervention group
Group type: COMPARATOR
Intervention: Simulated ischemia for 90 minutes followed by 120 minutes of reoxygenation
Number of subjects: 128
Study 12878949 — intervention group
Group type: COMPARATOR
Intervention: 210 minutes of aerobic incubation (time‐matched control)
Number of subjects: 128
Study 10654204 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 8 ml/kg (normal VT)
Number of subjects: 9
Study 10654204 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 12 ml/kg (high VT)
Number of subjects: 9
Study 10654204 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (S) at both tidal volumes (normal and high VT)
Number of subjects: 9
Study 8543398 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin treatment
Number of subjects: 0
Study 1858733 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with molar ratio of 0.9
Number of subjects: 69
Study 1858733 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with molar ratio of 1.2
Number of subjects: 69
Study 1858733 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with molar ratio of 1.4
Number of subjects: 69
Study 1858733 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed neonates
Number of subjects: 69
Study 1858733 — intervention group
Group type: COMPARATOR
Intervention: Human milk-fed neonates
Number of subjects: 69
Study 1858733 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed groups
Number of subjects: 69
Study 6351891 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day of slow release theophylline
Number of subjects: 18
Study 29178024 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0
Study 29178024 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 28409851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxygen and eszopiclone
Number of subjects: 20
Study 28409851 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Air control
Number of subjects: 20
Study 25755036 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for diabetes
Number of subjects: 18875
Study 25755036 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 18875
Study 23645340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) 1 hour before surgery and ramosetron immediately after surgery (Dexa‐Ra group, n = 135)
Number of subjects: 269
Study 23645340 — intervention group
Group type: COMPARATOR
Intervention: Ramosetron alone (Ra group, n = 134)
Number of subjects: 269
Study 20948489 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression bandage
Number of subjects: 0
Study 20948489 — intervention group
Group type: COMPARATOR
Intervention: Inelastic compression bandage
Number of subjects: 0
Study 18777429 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive intervention group (2-hour workshops + 2-hour practice session)
Number of subjects: 57
Study 18777429 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic intervention group (2-hour workshops)
Number of subjects: 57
Study 18777429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 57
Study 17909372 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (basic cohort)
Number of subjects: 122406
Study 17909372 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (after applying 5 restrictions)
Number of subjects: 122406
Study 17909372 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (multivariable Cox regression after 5 restrictions)
Number of subjects: 122406
Study 17909372 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (final estimate)
Number of subjects: 122406
Study 12707578 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapies
Number of subjects: 0
Study 12707578 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies of biologic agents
Number of subjects: 0
Study 10969369 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM with 0 N elevation force
Number of subjects: 40
Study 10969369 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM with 20 N and 40 N elevation force
Number of subjects: 40
Study 10969369 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM
Number of subjects: 40
Study 10969369 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM at 0 N elevation force
Number of subjects: 40
Study 10969369 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM at 40 N elevation force
Number of subjects: 40
Study 10969369 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 cadavers without ILM)
Number of subjects: 40
Study 8698440 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (5 mg twice daily)
Number of subjects: 22
Study 8698440 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium nitroprusside
Number of subjects: 22
Study 8698440 — intervention group
Group type: EXPERIMENTAL
Intervention: acetylcholine
Number of subjects: 22
Study 1729573 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 1234
Study 1729573 — intervention group
Group type: COMPARATOR
Intervention: Not living alone
Number of subjects: 1234
Study 6089862 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (22.5 g/l)
Number of subjects: 20
Study 6089862 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (36 g/l)
Number of subjects: 20
Study 6089862 — intervention group
Group type: COMPARATOR
Intervention: Control (no guar gum)
Number of subjects: 20
Study 31707982 — intervention group
Group type: EXPERIMENTAL
Intervention: Active comparator arms in head-to-head early RA trials
Number of subjects: 0
Study 31707982 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials in established RA
Number of subjects: 0
Study 29411495 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based health coaching (OHH, n = 722)
Number of subjects: 1522
Study 29411495 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control, n = 800)
Number of subjects: 1522
Study 26822582 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR resistance training
Number of subjects: 40
Study 24108148 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 150 mg/day + SSRI
Number of subjects: 189
Study 24108148 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/day + SSRI
Number of subjects: 189
Study 24108148 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 150 mg/day + SNRI
Number of subjects: 189
Study 24108148 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/day + SNRI
Number of subjects: 189
Study 24108148 — intervention group
Group type: COMPARATOR
Intervention: placebo + SSRI
Number of subjects: 189
Study 24108148 — intervention group
Group type: COMPARATOR
Intervention: placebo + SNRI
Number of subjects: 189
Study 22301929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Beverages (DBs)
Number of subjects: 318
Study 22301929 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 318
Study 22301929 — intervention group
Group type: COMPARATOR
Intervention: Attention Controls (ACs)
Number of subjects: 318
Study 19556946 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus ECT
Number of subjects: 70
Study 19556946 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus ECT
Number of subjects: 70
Study 19556946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride plus ECT
Number of subjects: 70
Study 17457088 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine
Number of subjects: 128
Study 17457088 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/abacavir
Number of subjects: 128
Study 17457088 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine/abacavir
Number of subjects: 128
Study 15047789 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps Baltimore program
Number of subjects: 0
Study 12613676 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (responding to both targets)
Number of subjects: 0
Study 12613676 — intervention group
Group type: COMPARATOR
Intervention: Control condition (responding to just the second target)
Number of subjects: 0
Study 12613676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed modality condition (randomly mixed target modality)
Number of subjects: 0
Study 9569128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan (CUP)
Number of subjects: 6
Study 9569128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose diacetate (CDA)
Number of subjects: 6
Study 9569128 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA)
Number of subjects: 6
Study 9569128 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylonitrile (PAN)
Number of subjects: 6
Study 7856453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical electrostimulation (30 minutes, twice a week for a total of 10 sessions, 18 msec duration, 100 Hz frequency)
Number of subjects: 103
Study 7856453 — intervention group
Group type: COMPARATOR
Intervention: Control groups (same pathology and number of subjects)
Number of subjects: 103
Study 2510261 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms/daily
Number of subjects: 243
Study 2510261 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg/daily
Number of subjects: 243
Study 182003 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine iodoxamate (Cholovue)
Number of subjects: 90
Study 182003 — intervention group
Group type: COMPARATOR
Intervention: Meglumine iodipamide (Cholografin)
Number of subjects: 90
Study 29482414 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical rehabilitation program (aqua aerobics, conditional swimming, recreational aerobics)
Number of subjects: 50
Study 29482414 — intervention group
Group type: COMPARATOR
Intervention: Control group program (conditional swimming and Pilates exercises)
Number of subjects: 50
Study 28720715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 37
Study 28720715 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 37
Study 26080882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 96
Study 26080882 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 96
Study 22708717 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive dual n-back program (working memory training group)
Number of subjects: 0
Study 22708717 — intervention group
Group type: COMPARATOR
Intervention: Adaptive visual search program (active placebo-control group)
Number of subjects: 0
Study 22708717 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group (received no practice)
Number of subjects: 0
Study 21234555 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (40 mg, nasal spray)
Number of subjects: 72
Study 21234555 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg, intramuscularly)
Number of subjects: 72
Study 21234555 — intervention group
Group type: COMPARATOR
Intervention: Both desmopressin and diclofenac
Number of subjects: 72
Study 19832818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (LNX) 8‐24 mg/day
Number of subjects: 171
Study 19832818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 19832818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100‐150 mg/day
Number of subjects: 171
Study 17875458 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 284
Study 17875458 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study 15746053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irinotecan at 80 mg/m(2)/day
Number of subjects: 25
Study 15746053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irinotecan at 70 mg/m(2)/day
Number of subjects: 25
Study 15746053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irinotecan (both dosages)
Number of subjects: 25
Study 15746053 — intervention group
Group type: COMPARATOR
Intervention: Food effect on oral irinotecan
Number of subjects: 25
Study 15746053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irinotecan
Number of subjects: 25
Study 15746053 — intervention group
Group type: COMPARATOR
Intervention: UGT1A1*28 genotype
Number of subjects: 25
Study 11212049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral recumbent head-down position
Number of subjects: 900
Study 11212049 — intervention group
Group type: COMPARATOR
Intervention: Lateral recumbent horizontal position
Number of subjects: 900
Study 11212049 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 900
Study 9678288 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (1 to 900 mg orally)
Number of subjects: 2606
Study 9678288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2606
Study 9678288 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 2606
Study 7986392 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly injections of GH (group 1)
Number of subjects: 28
Study 7986392 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily injections of GH (group 2)
Number of subjects: 28
Study 7986392 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (group 3)
Number of subjects: 28
Study 2692332 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium nitroprusside (SNP)
Number of subjects: 20
Study 2692332 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil
Number of subjects: 20
Study 31644499 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based couple intervention
Number of subjects: 487
Study 31644499 — intervention group
Group type: COMPARATOR
Intervention: Control (invitation letter for clinic-based couple HIV testing)
Number of subjects: 487
Study 28446804 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of amlodipine (10 mg) with irbesartan (100 mg)
Number of subjects: 125
Study 28446804 — intervention group
Group type: COMPARATOR
Intervention: Indapamide (1 mg) with irbesartan (100 mg) and amlodipine (5 mg)
Number of subjects: 125
Study 25204992 — intervention group
Group type: EXPERIMENTAL
Intervention: American cranberry (120 mg)
Number of subjects: 62
Study 25204992 — intervention group
Group type: COMPARATOR
Intervention: Routine prophylactic therapy (control group)
Number of subjects: 62
Study 23867808 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (110 μg indacaterol/50 μg glycopyrronium)
Number of subjects: 339
Study 23867808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 23867808 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149
Number of subjects: 339
Study 22192313 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training with static/dynamic exercises on a vibratory platform (Frequency: 30‐35 Hz; Amplitude: 2‐4 mm) for 6 weeks (3 sessions/week)
Number of subjects: 160
Study 22192313 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise protocol without vibration stimuli for 6 weeks (3 sessions/week)
Number of subjects: 160
Study 18821005 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Behavior Assessment System‐2nd edition (ABAS‐II)
Number of subjects: 0
Study 18821005 — intervention group
Group type: EXPERIMENTAL
Intervention: Scales of Independent Behavior‐Revised (SIB‐R)
Number of subjects: 0
Study 16865033 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-parent psychotherapy (CPP)
Number of subjects: 75
Study 16865033 — intervention group
Group type: COMPARATOR
Intervention: Case management plus community referral for individual treatment
Number of subjects: 75
Study 12872354 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine at a 30-minute standard infusion (Arm A)
Number of subjects: 112
Study 12872354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine at a fixed infusion rate of 10 mg/m2 per minute (Arm B)
Number of subjects: 112